Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference


Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, and Will Frederick, chief financial officer, will be hosting a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021, beginning at 12:00 p.m. EST. The Company will also host one-on-one meetings throughout the day.

The Company’s slide presentation will be available on the Investors page of the Simulations Plus website following the day’s meetings. For more information about the conference, please visit the BTIG event website or email [email protected]. Please note that participants must be preregistered to attend.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005318/en/

Simulations Plus Aktie

34,00 €
4,29 %
Die Simulations Plus Aktie hat heute starke Gewinne von 4,29 % aufzuweisen.
Leichtes Buy-Übergewicht bei Simulations Plus mit 3 Buy- gegenüber 0 Sell-Einschätzungen.
Das von der Community festgelegte Kursziel von 51 € für Simulations Plus bedeutet eine mögliche Steigerung um über 20% im Vergleich zu 34.0 €.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare